Looking to accelerate your stem cell therapy research? Creative Biolabs is pleased to launch its innovative set of induced pluripotent stem cell (iPSC)-based solutions.
SHIRLEY, NY, April 18, 2025 /24-7PressRelease/ — iPSCs, isolated from adult somatic cells, possess the unique ability to differentiate into any cell type within the human body. This ability distinguishes them as a very valuable tool for investigating disease mechanisms, developing new therapeutic strategies, and facilitating regenerative medicine. Creative Biolabs’ new service portfolio encompasses the full iPSC workflow, offering end-to-end assistance from reprogramming to early stages to downstream differentiation.
“We understand the challenge that researchers face in unraveling iPSC technology’s complexity. That is why we’ve established a portfolio across the board that makes every step of the way easy, from the germ of the original reprogramming to specific differentiation into cell types that you need.”
Creative Biolabs uses advanced approaches to generate high-quality iPSC lines that are specifically designed to address specific research needs. Their iPSC reprogramming services perform all aspects of iPSC reprogramming, from cell isolation and cultivation, reprogramming, expansion, and cryopreservation of potential iPSC clones to downstream validation using state-of-the-art technology, and they apply rigorous quality controls to ensure the reliability and reproducibility of the cell lines produced.
Besides its reprogramming service, Creative Biolabs also provides an extensive series of iPSC differentiation services. Researchers can utilize the company’s expert capabilities to direct iPSCs into a vast array of somatic cells to be employed for their research. These are but not limited to neural cells, cardiomyocytes, hepatocytes, and hematopoietic cells. The optimized differentiation protocols used by Creative Biolabs try to make processes as efficient and as clean as possible, which gives cell populations useful for a variety of applications, such as drug screening, toxicity testing, and transplantation studies.
Creative Biolabs also offers special differentiation services, such as functional astrocyte differentiation from iPSCs, providing access to breakthroughs in neurological disease research, such as Alzheimer’s and Parkinson’s disease.
“The launch of the complete range of iPSC-based services is an important step towards fulfilling our dedication to serving the scientific community,” said a scientist at Creative Biolabs. “We believe that our services will equip researchers with the tools and experience they require to propel the maximum advancement of stem cell therapy development.”
As a reliable partner in stem cell therapy research, Creative Biolabs continues to provide stable, affordable, and high-quality research solutions.
To learn more, please visit https://www.creative-biolabs.com/stem-cell-therapy/.
About Creative Biolabs
Creative Biolabs is a global biotechnology company that provides full-integrated, fast track stem cell therapy development solutions and services to researchers and pharmaceutical companies. Known for high-quality services and expert scientific consulting, Creative Biolabs endeavors to help researchers drive their projects from basic research to preclinical phases of research.
—
For the original version of this press release, please visit 24-7PressRelease.com here
